1y return+59.0%S&P 500 +20.9%
3y return+103.2%S&P 500 +68.5%
5y return+52.3%S&P 500 +74.5%
10y return+100.2%S&P 500 +256.5%
These returns are for its stock picks as disclosed on Form 13F: last quarter's holdings, valued at this quarter's prices. They miss trades within each quarter, short positions, options, bonds, cash and fees, so they aren't the returns its clients got.
$100 invested in its stock picks
Since June 30, 2016: $200 against $357 in the S&P 500.2
Novo Holdings A/sS&P 500 (SPY)
Top holdings
At the end of June 30, 2026. Change is in shares since the quarter before.2
| Stock | Value | Share of portfolio | Change |
|---|---|---|---|
| EWTXEdgewise Therapeutics Inc | $217.4M | 12.6% | |
| Asml Holding N VCUSIP N07059210 | $188.9M | 11.0% | |
| COAGHemab Therapeutics Hldgs Inc | $153.6M | 8.9% | New |
| BNBrookfield Corp | $149.5M | 8.7% | |
| MPLTMaplight Therapeutics Inc | $132.1M | 7.7% | |
| MIRMMirum Pharmaceuticals Inc | $131.7M | 7.6% | −15.1% |
| AVLNAvalyn Pharmaceuticals Inc | $127.8M | 7.4% | New |
| CRMSalesforce Inc | $61.6M | 3.6% | |
| AVBPArrivent Biopharma Inc | $52.1M | 3.0% | −22.8% |
| ELVNEnliven Therapeutics Inc | $50.8M | 2.9% | −21.9% |
| Crinetics Pharmaceuticals InCUSIP 22663K107 | $49.4M | 2.9% | −14.8% |
| Pharvaris N VCUSIP N69605108 | $48.4M | 2.8% | −20.0% |
| FNDFloor & Decor Hldgs Inc | $47.3M | 2.7% | New |
| PCVXVaxcyte Inc | $46.5M | 2.7% | −7.0% |
| FDMT4d Molecular Therapeutics In | $43.2M | 2.5% | −11.0% |
| VRDNViridian Therapeutics Inc | $39.2M | 2.3% | +6.7% |
| CLDXCelldex Therapeutics Inc New | $38.1M | 2.2% | −14.6% |
| ALMSAlumis Inc | $31.0M | 1.8% | New |
| XENEXenon Pharmaceuticals Inc | $29.3M | 1.7% | |
| BABAAlibaba Group Hldg Ltd | $24.7M | 1.4% | |
| DYNDyne Therapeutics Inc | $21.3M | 1.2% | New |
| BBOTBridgebio Oncology Therapeut | $17.1M | 1.0% | +2.9% |
| INSMInsmed Inc | $12.9M | 0.7% | New |
| Marqeta IncCUSIP 57142B104 | $7.2M | 0.4% | |
| LNZALanzatech Global Inc | $1.1M | 0.1% |
Best picks still held
How each current holding has done since the quarter it first appeared in its filings (up to six years back).
| Stock | Held since | Return since | Now worth |
|---|---|---|---|
| MIRMMirum Pharmaceuticals Inc | June 30, 2020 | +501.6% | $131.7M |
| Asml Holding N VCUSIP N07059210 | March 31, 2022 | +197.9% | $188.9M |
| PCVXVaxcyte Inc | June 30, 2022 | +167.1% | $46.5M |
| ELVNEnliven Therapeutics Inc | June 30, 2025 | +153.0% | $50.8M |
| EWTXEdgewise Therapeutics Inc | June 30, 2024 | +125.6% | $217.4M |
| MPLTMaplight Therapeutics Inc | December 31, 2025 | +104.0% | $132.1M |
| AVBPArrivent Biopharma Inc | March 31, 2024 | +94.5% | $52.1M |
| Crinetics Pharmaceuticals InCUSIP 22663K107 | March 31, 2022 | +70.5% | $49.4M |
| BNBrookfield Corp | September 30, 2023 | +36.2% | $149.5M |
| Pharvaris N VCUSIP N69605108 | March 31, 2021 | +23.6% | $48.4M |
Sold off last quarter
- Apogee Therapeutics IncCUSIP 03770N101 was $37.9M
- BMRNBiomarin Pharmaceutical Inc was $37.3M
- VALNValneva Se was $6.6M
Quarter by quarter
| Quarter | Its picks | S&P 500 |
|---|---|---|
| June 30, 2026 | +22.5% | +14.8% |
| March 31, 2026 | +2.0% | −4.6% |
| December 31, 2025 | +6.6% | +2.4% |
| September 30, 2025 | +19.5% | +7.8% |
| June 30, 2025 | +5.9% | +10.5% |
| March 31, 2025 | −7.0% | −4.6% |
| December 31, 2024 | −7.7% | +2.1% |
| September 30, 2024 | +15.7% | +5.4% |
| June 30, 2024 | −0.5% | +4.0% |
| March 31, 2024 | +4.5% | +10.0% |
| December 31, 2023 | +22.5% | +11.2% |
| September 30, 2023 | −4.6% | −3.6% |
| June 30, 2023 | +15.3% | +8.3% |
| March 31, 2023 | +13.2% | +7.0% |
| December 31, 2022 | −1.3% | +7.1% |
| September 30, 2022 | −4.4% | −5.3% |
| June 30, 2022 | −16.3% | −16.5% |
| March 31, 2022 | −13.0% | −4.9% |
| December 31, 2021 | −6.4% | +10.7% |
| September 30, 2021 | −10.7% | +0.3% |
Sources
Every number on this page points here. Each one links to the public record.
- 1SEC EDGAR: Novo Holdings A/s Form 13F filingshttps://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=1388325&type=13F-HR&dateb=&owner=include&count=40CIK 1388325
- 2SEC: 13F for the quarter ended June 30, 2026https://www.sec.gov/Archives/edgar/data/1388325/000138832526000042/Filed August 14, 2026 · accession 0001388325-26-000042